198 related articles for article (PubMed ID: 21414716)
1. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
Kachnic LA; Li L; Fournier L; Ferraiolo N; Dahm-Daphi J; Borgmann K; Willers H
Cancer Lett; 2011 Jun; 305(1):86-93. PubMed ID: 21414716
[TBL] [Abstract][Full Text] [Related]
2. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
3. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.
Wilson JB; Yamamoto K; Marriott AS; Hussain S; Sung P; Hoatlin ME; Mathew CG; Takata M; Thompson LH; Kupfer GM; Jones NJ
Oncogene; 2008 Jun; 27(26):3641-52. PubMed ID: 18212739
[TBL] [Abstract][Full Text] [Related]
4. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
Treszezamsky AD; Kachnic LA; Feng Z; Zhang J; Tokadjian C; Powell SN
Cancer Res; 2007 Aug; 67(15):7078-81. PubMed ID: 17671173
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light.
Dunn J; Potter M; Rees A; Rünger TM
Cancer Res; 2006 Dec; 66(23):11140-7. PubMed ID: 17145857
[TBL] [Abstract][Full Text] [Related]
6. Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.
Palle K; Vaziri C
Cell Cycle; 2011 May; 10(10):1625-38. PubMed ID: 21478670
[TBL] [Abstract][Full Text] [Related]
7. Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining.
Houghtaling S; Newell A; Akkari Y; Taniguchi T; Olson S; Grompe M
Hum Mol Genet; 2005 Oct; 14(20):3027-33. PubMed ID: 16135554
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R.
Xiao H; Xiao Q; Zhang K; Zuo X; Shrestha UK
Ann Hematol; 2010 Apr; 89(4):399-404. PubMed ID: 19756599
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.
Ferrer M; de Winter JP; Mastenbroek DC; Curiel DT; Gerritsen WR; Giaccone G; Kruyt FA
Cancer Gene Ther; 2004 Aug; 11(8):539-46. PubMed ID: 15192709
[TBL] [Abstract][Full Text] [Related]
10. The Fanconi anemia group A protein modulates homologous repair of DNA double-strand breaks in mammalian cells.
Yang YG; Herceg Z; Nakanishi K; Demuth I; Piccoli C; Michelon J; Hildebrand G; Jasin M; Digweed M; Wang ZQ
Carcinogenesis; 2005 Oct; 26(10):1731-40. PubMed ID: 15905196
[TBL] [Abstract][Full Text] [Related]
11. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
12. Impaired removal of DNA interstrand cross-link in Nijmegen breakage syndrome and Fanconi anemia, but not in BRCA-defective group.
Tsuchida K; Komatsu K
Cancer Sci; 2008 Nov; 99(11):2238-43. PubMed ID: 18771529
[TBL] [Abstract][Full Text] [Related]
13. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
14. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
15. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
16. Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway.
Peremartí J; Ramos F; Marcos R; Hernández A
Toxicol Sci; 2014 Nov; 142(1):93-104. PubMed ID: 25092648
[TBL] [Abstract][Full Text] [Related]
17. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
18. Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery.
Tripathi K; Mani C; Clark DW; Palle K
Oncotarget; 2016 Mar; 7(11):12537-53. PubMed ID: 26871286
[TBL] [Abstract][Full Text] [Related]
19. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
Bau JT; Kurz EU
Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
[TBL] [Abstract][Full Text] [Related]
20. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
Ohashi A; Zdzienicka MZ; Chen J; Couch FJ
J Biol Chem; 2005 Apr; 280(15):14877-83. PubMed ID: 15671039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
